Marseille, France-based Volta develops technology to assist electrophysiologic physicians in treating complex cardiac arrhythmias. In December 2020, the FDA cleared Volta’s VX1 AI software for interventional cardiac electrophysiology.
The tool uses machine and deep learning algorithms. It assists operators in the real-time manual annotation of 3D anatomical and electrical maps of the human atria. Its uses included during an Afib or atrial tachycardia. Volta believes the detection and patient-specific localization of abnormal regions may eventually help physicians better decide where they need to intervene to burn (radiofrequency) or freeze (cryotherapy) faulty electrical pathways.
VX1 could offer a faster and more accurate way to identify zones of interes…